Spectrum of Infections Occurring in Patients of Autoimmune Rheumatic Diseases on Treatment with Biological Versus Conventional Disease-modifying Antirheumatic Drugs: A Comparative Study

Overview

Journal J Family Med Prim Care

Specialty Public Health

Date 2022 Nov 17

PMID 36387744

Authors

Partisha Gupta

Prasanta Padhan

Nishant Bhargava

Pradip Kumar Behera

Krishna Padarabinda Tripathy

Sudhansu Sekhar Panda

Affiliations

Soon will be listed here.

Abstract

Background: The era of biological therapy has revolutionized in the management of autoimmune rheumatic diseases. There have been conflicting results about the incidence of infections related to these drugs. The purpose of this study was to compare the spectrum and severity of infection between patients on biological disease-modifying antirheumatic drugs (bDMARDs) versus conventional disease-modifying antirheumatic drugs (cDMARDs).

Materials And Methods: This hospital-based prospective observational study was conducted in a tertiary care hospital, and a total 200 patients were enrolled in this study. Patients on either bDMARDs or cDMARDs for at least six weeks presenting with evidence of infection were included. Patients with known immunodeficiency states, multiple comorbidities, and patients on prednisolone >7.5 mg were excluded. Data was expressed as percentage and mean ± SD. Kolmogorov-Smirnov analysis was performed for checking linearity of the data, and analysis of variance (ANOVA) followed by Tukey's HSD test were used to test the significance of difference between more than two parameters in parametric data.

Results: Rheumatoid arthritis in 58 patients (29%) were the commonest ones presenting with infections, followed by systemic lupus erythematosus in 37 patients (18.5%). 135 patients (67.5%) were on cDMARDs and 65 patients (32.5%) on bDMARDs. Respiratory tract infection in 47 (34.8%) patients was found to be the commonest infection due to cDMARDs. Incidence of infection was higher with biologics, and types of infection in patients receiving infliximab and etanercept were significantly different from that of cDMARDs. Patients receiving etanercept had higher risk of infections and re-infections, but they were milder compared to cDMARDs. A significantly higher frequency of re-infection was found in patients who had not received vaccination.

Conclusion: This study emphasizes that TNF-α inhibitors are significantly associated with higher risk of infections. Patients on etanercept have significantly higher but milder infections as compared to cDMARDs. Vaccination plays a pivotal role in prevention of re-infections.

Citing Articles

Disproportionality Analysis and Characterisation of Medication Errors in EudraVigilance: Exploring Findings on Sexes and Age Groups.

Pera V, Kors J, van Mulligen E, de Wilde M, Rijnbeek P, Verhamme K Drug Saf. 2024; 48(1):59-74.

PMID: 39300043 PMC: 11711134. DOI: 10.1007/s40264-024-01478-6.

Opportunistic Infections, Mortality Risk, and Prevention Strategies in Patients With Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome.

Czech M, Cuellar-Rodriguez J, Patel B, Groarke E, Cowen E, Turturice B Open Forum Infect Dis. 2024; 11(7):ofae405.

PMID: 39077052 PMC: 11285395. DOI: 10.1093/ofid/ofae405.

The Minor Phytocannabinoid Delta-8-Tetrahydrocannabinol Attenuates Collagen-Induced Arthritic Inflammation and Pain-Depressed Behaviors.

Vanegas S, Zaki A, Dealy C, Kinsey S J Pharmacol Exp Ther. 2024; 391(2):222-230.

PMID: 38834355 PMC: 11493440. DOI: 10.1124/jpet.124.002189.

References

Richter A, Listing J, Schneider M, Klopsch T, Kapelle A, Kaufmann J . Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2015; 75(9):1667-73. PMC: 5013078. DOI: 10.1136/annrheumdis-2015-207838. View

Curtis J, Yang S, Patkar N, Chen L, Singh J, Cannon G . Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014; 66(7):990-7. PMC: 5059836. DOI: 10.1002/acr.22281. View

van Vollenhoven R, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson I . Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012; 379(9827):1712-20. DOI: 10.1016/S0140-6736(12)60027-0. View

Saha S, Yoshida S, Ohba K, Matsui K, Matsuda T, Takeshita F . A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus. Virology. 2006; 354(1):48-57. DOI: 10.1016/j.virol.2006.04.015. View

Jick S, Lieberman E, Rahman M, Choi H . Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006; 55(1):19-26. DOI: 10.1002/art.21705. View

Walters H, Pan N, Lehman T, Adams A, Huang W, Sitaras L . A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors. Clin Rheumatol. 2014; 34(3):457-64. PMC: 4351171. DOI: 10.1007/s10067-014-2779-8. View

Germano V, Cattaruzza M, Osborn J, Tarantino A, Di Rosa R, Salemi S . Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists. J Transl Med. 2014; 12:77. PMC: 3994399. DOI: 10.1186/1479-5876-12-77. View

Aaltonen K, Tuulikki Joensuu J, Virkki L, Sokka T, Aronen P, Relas H . Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol. 2015; 42(3):372-8. DOI: 10.3899/jrheum.140853. View

Quartuccio L, Zabotti A, Del Zotto S, Zanier L, De Vita S, Valent F . Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data. J Adv Res. 2018; 15:87-93. PMC: 6300460. DOI: 10.1016/j.jare.2018.09.003. View

10.

Dixon W, Watson K, Lunt M, Hyrich K, Silman A, Symmons D . Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006; 54(8):2368-76. DOI: 10.1002/art.21978. View

11.

Ozen G, Pedro S, England B, Mehta B, Wolfe F, Michaud K . Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease-Modifying Antirheumatic Drugs. ACR Open Rheumatol. 2019; 1(7):424-432. PMC: 6858027. DOI: 10.1002/acr2.11064. View

12.

Kammuller M, Tsai T, Griffiths C, Kapoor N, Kolattukudy P, Brees D . Inhibition of IL-17A by secukinumab shows no evidence of increased infections. Clin Transl Immunology. 2017; 6(8):e152. PMC: 5579471. DOI: 10.1038/cti.2017.34. View

13.

Haraoui B, Bykerk V . Etanercept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag. 2008; 3(1):99-105. PMC: 1936291. DOI: 10.2147/tcrm.2007.3.1.99. View

14.

Schneeweiss S, Setoguchi S, Weinblatt M, Katz J, Avorn J, Sax P . Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007; 56(6):1754-64. DOI: 10.1002/art.22600. View

15.

. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society.... Am J Respir Crit Care Med. 2000; 161(4 Pt 2):S221-47. DOI: 10.1164/ajrccm.161.supplement_3.ats600. View

16.

Zhang Z, Fan W, Yang G, Xu Z, Wang J, Cheng Q . Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017; 7(3):e012567. PMC: 5372052. DOI: 10.1136/bmjopen-2016-012567. View

17.

Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli E . Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012; 12(2):225-9. DOI: 10.1016/j.autrev.2012.06.008. View

18.

Galloway J, Hyrich K, Mercer L, Dixon W, Fu B, Ustianowski A . Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with.... Rheumatology (Oxford). 2010; 50(1):124-31. PMC: 3105607. DOI: 10.1093/rheumatology/keq242. View